Bone as an Endocrine Organ

Bone as an Endocrine Organ refers to the concept that bone tissue is not merely a structural framework for the body, but also functions as an active endocrine organ by producing and secreting hormones that influence systemic physiology. These hormones participate in the regulation of mineral metabolism, energy homeostasis, and cross-talk with other organs such as the pancreas, kidneys, and brain. This paradigm extends the traditional view of bone beyond its mechanical and metabolic roles, highlighting its integrative role in whole-body endocrine networks.

Bone-Derived Hormones

Osteocalcin

Osteocalcin is a non-collagenous protein secreted primarily by osteoblasts during bone formation. It exists in two forms: carboxylated and undercarboxylated, with the undercarboxylated form acting as a hormone. Osteocalcin influences systemic glucose metabolism by enhancing insulin secretion from pancreatic β-cells and improving insulin sensitivity in peripheral tissues such as muscle and adipose tissue. It also stimulates the proliferation of β-cells and increases energy expenditure by promoting adiponectin release from adipocytes.

Fibroblast Growth Factor 23 (FGF23)

FGF23 is a hormone produced mainly by osteocytes that plays a critical role in phosphate homeostasis. It acts on the kidneys to reduce phosphate reabsorption and decreases the production of 1,25-dihydroxyvitamin D (calcitriol), thereby regulating serum phosphate concentration and vitamin D metabolism. Dysregulation of FGF23 is implicated in disorders such as hypophosphatemic rickets and chronic kidney disease-related mineral and bone disorder (CKD-MBD).

Sclerostin

Sclerostin, produced mainly by osteocytes, acts as a paracrine and endocrine factor by inhibiting the Wnt/β-catenin signaling pathway, which is critical for bone formation. While primarily regulating bone remodeling locally, sclerostin also influences systemic mineral metabolism and may indirectly affect glucose metabolism and fat mass, although its endocrine roles beyond bone remain under investigation.

Lipocalin 2

Lipocalin 2 is another osteoblast-derived hormone implicated in the regulation of appetite and energy metabolism. It crosses the blood-brain barrier and acts on the hypothalamus to suppress appetite, linking bone physiology to central regulation of food intake and body weight.

Mechanisms of Hormone Secretion and Action

Bone cells—osteoblasts, osteocytes, and to a lesser extent osteoclasts—produce endocrine factors in response to mechanical stimuli, nutrient availability, and systemic hormonal signals. These hormones enter the circulation and exert endocrine effects on distant organs. The secretion of bone-derived hormones is tightly regulated by local bone remodeling activity and systemic factors including parathyroid hormone (PTH), vitamin D, and inflammatory cytokines.

Osteocalcin’s hormonal activity requires decarboxylation, a process linked to bone resorption and acidification of the bone microenvironment by osteoclasts. This coupling ensures that bone remodeling is synchronized with endocrine signaling.

FGF23 secretion is regulated by serum phosphate levels, vitamin D, and PTH, creating feedback loops that maintain mineral balance.

Physiological Roles of Bone as an Endocrine Organ

Regulation of Mineral Metabolism

Bone-derived hormones such as FGF23 and osteocalcin coordinate the metabolism of calcium, phosphate, and vitamin D. FGF23 reduces renal phosphate reabsorption and suppresses vitamin D activation, preventing hyperphosphatemia. Osteocalcin indirectly influences calcium homeostasis by modulating insulin and energy metabolism, which are closely linked to bone remodeling.

Energy Metabolism and Glucose Homeostasis

Osteocalcin enhances pancreatic insulin secretion and insulin sensitivity, thereby linking bone remodeling to glucose metabolism. This establishes bone as a regulator of systemic energy balance, influencing muscle function, adiposity, and metabolic health.

Lipocalin 2’s appetite-suppressing effects further integrate bone into the regulation of energy intake and expenditure.

Cross-talk with Other Organs

Bone-derived hormones interact with multiple organ systems, including:

• Pancreas: Osteocalcin stimulates insulin secretion.
• Kidneys: FGF23 regulates phosphate excretion and vitamin D metabolism.
• Brain: Lipocalin 2 modulates appetite and possibly cognitive functions.
• Adipose Tissue: Osteocalcin enhances adiponectin release, improving insulin sensitivity.

This inter-organ communication positions bone as a central player in endocrine networks coordinating metabolism and homeostasis.

Clinical Implications

Recognition of bone as an endocrine organ has transformed understanding of metabolic diseases and bone disorders. Alterations in bone-derived hormone secretion are linked to:

• Type 2 diabetes mellitus, through impaired osteocalcin activity.
• Chronic kidney disease, through dysregulated FGF23 leading to mineral and bone disorders.
• Obesity and metabolic syndrome, influenced by lipocalin 2 and osteocalcin pathways.
• Osteoporosis and fracture risk, where local and systemic endocrine factors modulate bone remodeling.

Therapeutic interventions targeting bone hormones, such as monoclonal antibodies against sclerostin or modulators of FGF23, are emerging as treatments for metabolic bone diseases and related systemic conditions.

Integration of Bone Endocrine Function with Bone Remodeling

Bone remodeling is a dynamic process involving bone resorption by osteoclasts and formation by osteoblasts. The endocrine functions of bone are intricately linked to this remodeling cycle. Hormone secretion is often coupled to bone turnover; for example, osteocalcin requires resorption-associated decarboxylation to become hormonally active. This coupling ensures that systemic metabolic signals are synchronized with skeletal health and mechanical adaptation.

Furthermore, bone endocrine function is influenced by mechanical loading, which not only shapes bone architecture but also modulates hormone secretion, integrating physical activity with metabolic regulation.

Future Directions in Bone Endocrinology

Ongoing research is expanding the repertoire of bone-derived hormones and their systemic targets. Novel factors and mechanisms continue to emerge, deepening understanding of bone’s role in:

• Immune regulation and inflammation.
• Central nervous system function.
• Cardiovascular health.

Advanced molecular and clinical studies aim to unravel the complex endocrine networks involving bone, with potential to identify new biomarkers and therapeutic targets for metabolic, skeletal, and systemic diseases.